Phase 3 Obesity trials recruiting now

All Obesity trials, every phase

Other phases for Obesity

Phase 3 Obesity trials

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 203 locations
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 204 locations
• A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
  NCT07670884 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
  NCT07284511 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 650 locations
• A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
  NCT06994650 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
  NCT06974851 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 117 locations
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 82 locations
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · 121 locations
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 303 locations
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1676 locations
• A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
  NCT07220772 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · 1 location
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 74 locations
• A Study of BGM0504 Injection in Participants with Obesity or Overweight
  NCT06704581 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of BGM0504 in Early T2DM With Obesity
  NCT07743983 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of DA-302168S in Participants With Overweight/Obesity
  NCT07629544 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
  NCT07734311 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 157 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 324 locations
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 115 locations
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 374 locations
• A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
  NCT07255209 · Phase: Phase 3 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
  NCT06931028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 135 locations
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 120 locations
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 34 locations
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 136 locations
• A Study of Pitolisant in Patients With Prader-Willi Syndrome
  NCT06366464 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female) · 57 locations
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
  NCT06439277 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 69 locations
• A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
  NCT07387094 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
  NCT07434050 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 212 locations
• A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
  NCT07446439 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 10 locations
• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
  NCT07670416 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
  NCT07775404 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 98 locations
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 100 locations
• A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
  NCT06760546 · Phase: Phase 3 · Ages: 4 Years and older · Sex: All (male and female) · 11 locations
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
  NCT07339423 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 74 locations
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 80 locations
• AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 92 locations
• AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07509307 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 81 locations
• Bariatric SUrgery With Mesh REpair of Ventral Hernia: a Randomized Controlled Trial
  NCT05488288 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
  NCT07075146 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
  NCT06934655 · Phase: Phase 3 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
  NCT05935826 · Phase: Phase 3 · Ages: 13 Years to 18 Years · Sex: All (male and female) · 1 location
• Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
  NCT07297290 · Phase: Phase 3 · Ages: 20 Years to 59 Years · Sex: All (male and female) · 2 locations
• Effect of Semaglutide in Patients With Psoriasis and Obesity
  NCT06937060 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
  NCT06423599 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 71 locations
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 152 locations
• Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
  NCT07279194 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
  NCT07469800 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 59 locations
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 167 locations
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
  NCT07036172 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
  NCT07481747 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 45 locations
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · 782 locations
• Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
  NCT06893016 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
  NCT07292441 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 87 locations
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 74 locations
• Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
  NCT04578652 · Phase: Phase 3 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• Food Prescriptions to Promote Affordable Diets
  NCT05309395 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · 1 location
• Food-Body-Mind Intervention (16 Weeks)
  NCT06597474 · Phase: Phase 2, Phase 3 · Ages: 3 Years to 5 Years · Sex: All (male and female) · 1 location
• GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
  NCT05316935 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
  NCT06379113 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
  NCT07294950 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.
  NCT07332273 · Phase: Phase 3 · Ages: 25 Years to 60 Years · Sex: All (male and female) · 5 locations
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 57 locations
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
  NCT07225686 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 61 locations
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1314 locations
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 374 locations
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 183 locations
• Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents
  NCT03516968 · Phase: Phase 3 · Ages: 5 Years to 18 Years · Sex: All (male and female) · 4 locations
• PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
  NCT04971720 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
  NCT07150975 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
  NCT07528027 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 4 locations
• Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery
  NCT05816798 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
  NCT07770841 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
  NCT05819853 · Phase: Phase 3 · Ages: 12 Years to 35 Years · Sex: Female · 2 locations
• Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
  NCT06499857 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
  NCT06896981 · Phase: Phase 2, Phase 3 · Ages: 10 Years to 45 Years · Sex: Female · 2 locations
• Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
  NCT05653258 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
  NCT05316493 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.